Structure–Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,484 · see citing works

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · see citing works

NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities

Gottlieb, H. E., Kotlyar, V., & Nudelman, A. (1997) · The Journal of Organic Chemistry · doi:10.1021/jo971176v · Cited by 3,754 · see citing works

SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works

[19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors

Ballesteros, J. A., & Weinstein, H. (1995) · Methods in neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 3,001 · see citing works

International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819 · see citing works

Alzheimer's disease

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works

Microglia in neurodegenerative disease

Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · see citing works

Identification and Functional Characterization of Brainstem Cannabinoid CB₂Receptors

Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470 · see citing works

Untitled work

Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284 · see citing works

Designed Multiple Ligands. An Emerging Drug Discovery Paradigm

Morphy, R., & Ranković, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,237 · see citing works

Neurobiology of butyrylcholinesterase

Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1035 · Cited by 896 · see citing works

Untitled work

(2016) · London School of Economics and Political Science Research Online (London School of Economics and Political Science) · Cited by 874 · see citing works

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 745 · see citing works

Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction

Maurice, T., Lockhart, B. P., & Privat, A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01032-7 · Cited by 524 · see citing works

Agonist‐inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630

Ross, R. A., Brockie, H. C., Stevenson, L., Murphy, V. L., Templeton, F., Makriyannis, A., & Pertwee, R. G. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702351 · Cited by 407 · see citing works

Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation

Ehrhart, J. C., Obregon, D. F., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J., & Shytle, R. D. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-29 · Cited by 379 · see citing works

Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

Fernández‐Ruíz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.11.001 · Cited by 362 · see citing works

Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study

Núñez, E., Benito, C., Pazos, M. R., Barbáchano, A., Fajardo, O., González, S. R., Tolón, R. M., & Romero, J. (2004) · Synapse · doi:10.1002/syn.20050 · Cited by 334 · see citing works

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li, Q., Yang, H., Chen, Y., & Sun, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.062 · Cited by 331 · see citing works

A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease

Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T., & Somogyi, M. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01412 · Cited by 323 · see citing works

Butyrylcholinesterase in the life cycle of amyloid plaques

Guillozet-Bongaarts, A. L., Mesulam, M. M., Smiley, J. F., & Mash, D. C. (1997) · Annals of Neurology · doi:10.1002/ana.410420613 · Cited by 312 · see citing works

Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia

Mesulam, M. M., & Geula, C. (1994) · Annals of Neurology · doi:10.1002/ana.410360506 · Cited by 259 · see citing works

Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice

Martín-Moreno, A. M., Brera, B., Spuch, C., Carro, E., García‐García, L., Delgado, M., Pozo, M. A., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-8 · Cited by 246 · see citing works

Synthetic cannabinoid WIN55,212‐2 inhibits generation of inflammatory mediators by IL‐1β‐stimulated human astrocytes

Sheng, W. S., Hu, S., Min, X. M., Cabral, G. A., Lokensgard, J. R., & Peterson, P. K. (2004) · Glia · doi:10.1002/glia.20108 · Cited by 246 · see citing works

Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.

Alas, S., & Bonavida, B. (2003) · PubMed · Cited by 240 · see citing works

Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability

Wright, C. I., Geula, C., & Mesulam, M.-M. (1993) · Annals of Neurology · doi:10.1002/ana.410340312 · Cited by 237 · see citing works

CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients

Solas, M., Francis, P. T., Franco, R., & Ramírez, M. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.005 · Cited by 209 · see citing works

Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1Cannabinoid Receptor Antagonists

Lange, J. H. M., van Stuivenberg, H. H., Coolen, H. K. A. C., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040843r · Cited by 181 · see citing works

Development of an in-vivo active reversible butyrylcholinesterase inhibitor

Košak, U., Brus, B., Knez, D., Šink, R., Žakelj, S., Trontelj, J., Pišlar, A. H., Šlenc, J., Gobec, M., Živin, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39495 · Cited by 176 · see citing works

Activation of the CB2 receptor system reverses amyloid-induced memory deficiency

Wu, J., Bie, B., Yang, H., Xu, J. J., Brown, D. L., & Naguib, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.011 · Cited by 174 · see citing works

Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia

Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174 · see citing works

cAMP detection methods in HTS: selecting the best from the rest

Williams, C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1306 · Cited by 170 · see citing works

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 163 · see citing works

Endocannabinoid signalling in innate and adaptive immunity

Chiurchiù, V., Battistini, L., & Maccarrone, M. (2015) · Immunology · doi:10.1111/imm.12441 · Cited by 158 · see citing works

Multitarget Drug Design Strategy: Quinone–Tacrine Hybrids Designed To Block Amyloid‑β Aggregation and To Exert Anticholinesterase and Antioxidant Effects

Nepovimová, E., Uliassi, E., Korábečný, J., Peña‐Altamira, E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 154 · see citing works

Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide‐induced nitric oxide release in astrocyte cultures

Molina‐Holgado, F., Molina‐Holgado, E., Guaza, C., & Rothwell, N. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10165 · Cited by 148 · see citing works

A new efficient synthesis of isothiocyanates from amines using di-tert-butyl dicarbonate

Munch, H. K., Hansen, J. S., Pittelkow, M., Christensen, J. B., & Boas, U. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.03.045 · Cited by 147 · see citing works

<i>In vitro</i>and<i>in vivo</i>characterization of A‐796260: a selective cannabinoid CB₂receptor agonist exhibiting analgesic activity in rodent pain models

Yao, B. B., Hsieh, G. C., Frost, J. M., Fan, Y., Garrison, T. R., Daza, A. V., Grayson, G. K., Zhu, C. Z., Pai, M., Chandran, P., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707568 · Cited by 140 · see citing works

Emerging Role of High-Mobility Group Box 1 (HMGB1) in Liver Diseases

Chen, R., Hou, W., Zhang, Q., Kang, R., Fan, X., & Tang, D. (2013) · Molecular Medicine · doi:10.2119/molmed.2013.00099 · Cited by 130 · see citing works

Tacrine–Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity

Nepovimová, E., Korábečný, J., Doležal, R., Babkova, K., Ondřejíček, A., Jun, D., Šepsová, V., Horova, A., Hrabinová, M., Soukup, O., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01325 · Cited by 129 · see citing works

Reporter-gene systems for the study of G-protein-coupled receptors

Hill, S. J. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00091-1 · Cited by 123 · see citing works

Marker proteins for gene expression

Wood, K. V. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80009-3 · Cited by 116 · see citing works

Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode

Sawatzky, E., Wehle, S., Kling, B., Wendrich, J., Bringmann, G., Sotriffer, C., Heilmann, J., & Decker, M. W. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01674 · Cited by 103 · see citing works

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer’s Disease Agents

Montanari, S., Scalvini, L., Bartolini, M., Belluti, F., Gobbi, S., Andrisano, V., Ligresti, A., Marzo, V. D., Rivara, S., Mor, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00609 · Cited by 87 · see citing works

Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer’s Disease

Špilovská, K., Korábečný, J., Nepovimová, E., Doležal, R., Mezeiová, E., Soukup, O., & Kuča, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026605666160927152728 · Cited by 86 · see citing works

Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance

Naour, M. L., Akgün, E., Yekkirala, A. S., Lunzer, M. M., Powers, M. D., Kalyuzhny, A. E., & Portoghese, P. S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005219 · Cited by 85 · see citing works

Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones

Stößel, A., Schlenk, M., Hinz, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400336x · Cited by 85 · see citing works

Synthesis, Biological Evaluation, and Computational Studies of Tri- and Tetracyclic Nitrogen-Bridgehead Compounds as Potent Dual-Acting AChE Inhibitors andhH3Receptor Antagonists

Darras, F. H., Pockes, S., Huang, G., Wehle, S., Straßer, A., Wittmann, H., Nimczick, M., Sotriffer, C., & Decker, M. W. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn4002126 · Cited by 80 · see citing works

Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse

Maurice, T., Strehaïano, M., Siméon, N., Bertrand‐Gaday, C., & Chatonnet, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.08.026 · Cited by 73 · see citing works

Type-2 cannabinoid receptors in neurodegeneration

Bisogno, T., Oddi, S., Piccoli, A., Fazio, D., & Maccarrone, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.021 · Cited by 71 · see citing works

Benzimidazol‐Derivate und verwandte Heterocyclen III. Synthese von 1‐Aminoalkyl‐2‐nenzyl‐nitro‐benzimidazolen

Hunger, A., Kebrle, J., Rossi, A., & Hoffmann, K. J. (1960) · Helvetica Chimica Acta · doi:10.1002/hlca.19600430412 · Cited by 70 · see citing works

Novel benzimidazole derivatives as selective CB2 agonists

Pagé, D., Balaux, É., Boisvert, L., Liu, Z., Milburn, C., Tremblay, M., Wei, Z., Woo, S., Luo, X., Cheng, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.073 · Cited by 66 · see citing works

Design, Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel Tacrine Derivatives with a Combination of Acetylcholinesterase Inhibition and Cannabinoid CB1Receptor Antagonism

Lange, J. H. M., Coolen, H. K. A. C., van der Neut, M. A. W., Borst, A. J. M., Stork, B., Verveer, P. C., & Kruse, C. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901614b · Cited by 61 · see citing works

Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease

Grünblatt, E., Zander, N., Bartl, J., Li, J., Monoranu, C., Arzberger, T., Ravid, R., Roggendorf, W., Gerlach, M., & Riederer, P. F. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12402 · Cited by 59 · see citing works

Amine substitution of quinazolinones leads to selective nanomolar AChE inhibitors with ‘inverted’ binding mode

Darras, F. H., Wehle, S., Huang, G., Sotriffer, C., & Decker, M. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.06.045 · Cited by 58 · see citing works

Transcriptional Activation of the Macrophage Migration-Inhibitory Factor Gene by the Corticotropin-Releasing Factor is Mediated by the Cyclic Adenosine 3',5'-Monophosphate Responsive Element-Binding Protein CREB in Pituitary Cells

Waeber, G., Thompson, N. A., Chautard, T., Steinmann, M., NICOD, P. H., Pralong, F. P., Calandra, T., & Gaillard, R. C. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.5.0109 · Cited by 58 · see citing works

Synthesis and Structure−Activity Relationships of Cyanoguanidine-Type and Structurally Related Histamine H4Receptor Agonists

Igel, P., Geyer, R., Straßer, A., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900526h · Cited by 57 · see citing works

Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response

Zheng, Y., Wang, Q., Li, T., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw131 · Cited by 56 · see citing works

Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease

González-Naranjo, P., Pérez-Macías, N., Campillo, N. E., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.026 · Cited by 50 · see citing works

Pharmacological Profile of Histaprodifens at Four Recombinant Histamine H1 Receptor Species Isoforms

Straßer, A., Striegl, B., Wittmann, H., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129601 · Cited by 45 · see citing works

The dual-acting AChE inhibitor and H3 receptor antagonist UW-MD-72 reverses amnesia induced by scopolamine or dizocilpine in passive avoidance paradigm in rats

Sadek, B. S., Khan, N., Darras, F. H., Pockes, S., & Decker, M. W. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.08.022 · Cited by 42 · see citing works

Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells

Kato, K., Nomoto, M., Izumi, H., Ise, T., Nakano, S., Niho, Y., & Kohno, K. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00168-8 · Cited by 40 · see citing works

The dual-acting H3 receptor antagonist and AChE inhibitor UW-MD-71 dose-dependently enhances memory retrieval and reverses dizocilpine-induced memory impairment in rats

Khan, N., Saad, A. K., Nurulain, S. M., Darras, F. H., Decker, M. W., & Sadek, B. S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.022 · Cited by 40 · see citing works

Aminobenzimidazoles and Structural Isomers as Templates for Dual‐Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders

Dolles, D., Nimczick, M., Scheiner, M., Ramler, J., Stadtmüller, P., Sawatzky, E., Drakopoulos, A., Sotriffer, C., Wittmann, H., Straßer, A., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500418 · Cited by 39 · see citing works

Modulation of GPCRs by monovalent cations and anions

Straßer, A., Wittmann, H., Schneider, E. H., & Seifert, R. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1073-2 · Cited by 36 · see citing works

Neuropathology of Alzheimer's Disease and its Variants

Duyckaerts, C. J., & Dickson, D. W. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch10 · Cited by 34 · see citing works

New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds

Nimczick, M., & Decker, M. W. (2015) · ChemMedChem · doi:10.1002/cmdc.201500041 · Cited by 28 · see citing works

Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers

Perrey, D. A., Gilmour, B. P., Thomas, B. F., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4004759 · Cited by 27 · see citing works

Synthesis and biological activity of splitomicin analogs targeted at human NAD+-dependent histone deacetylases (sirtuins)

Freitag, M., Schemies, J., Larsen, T., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.01.026 · Cited by 26 · see citing works

NOpiates: Novel Dual Action Neuronal Nitric Oxide Synthase Inhibitors with μ-Opioid Agonist Activity

Renton, P., Green, B. J., Maddaford, S. P., Rakhit, S., & Andrews, J. S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200268w · Cited by 23 · see citing works

Cytotoxic properties of the alkaloid rutaecarpine and its oligocyclic derivatives and chemical modifications to enhance water-solubility

Huang, G., Drakopoulos, A., Saedtler, M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.045 · Cited by 20 · see citing works

Sodium binding to hH3R and hH4R — a molecular modeling study

Wittmann, H., Seifert, R., & Straßer, A. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2394-2 · Cited by 15 · see citing works

Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors

Dolles, D., & Decker, M. W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101011-2.00005-2 · Cited by 7 · see citing works

Computational Methods in Multitarget Drug Discovery

Bottegoni, G., & Cavalli, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101011-2.00009-x · Cited by 6 · see citing works

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds

Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498 · see citing works

From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology

Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works

DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles

Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141 · see citing works

Highly Selective Butyrylcholinesterase Inhibitors With Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer’s Disease Mouse Model

Hoffmann, M., Stiller, C., Endres, E., Scheiner, M., Gunesch, S., Sotriffer, C., Maurice, T., & Decker, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01012 · Cited by 105 · see citing works

Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo

Scheiner, M., Dolles, D., Gunesch, S., Hoffmann, M., Nabissi, M., Marinelli, O., Naldi, M., Bartolini, M., Petralla, S., Poeta, E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00623 · Cited by 49 · see citing works

Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors

Mukherjee, S., Adams, M., Whiteaker, K. L., Daza, A. V., Kage, K., Cassar, S. C., Meyer, M., & Yao, B. B. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.09.058 · Cited by 99 · see citing works

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor

Buckley, N. E., McCoy, K. L., Mezey, É., Bonner, T. I., Zimmer, A. M., Felder, C. C., Glass, M., & Zimmer, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00211-9 · Cited by 544 · see citing works

Identification and biochemical analyses of selective CB2 agonists

Scott, C. E., Tang, Y., Alt, A. J., Burford, N. T., Gerritz, S. W., Ogawa, L. M., Zhang, L., & Kendall, D. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.054 · Cited by 9 · see citing works

Design, synthesis and evaluation of fluorescent CB2 cannabinoid receptor ligands

Holt, C. J. (2009) · Nottingham ePrints (University of Nottingham) · Cited by 1 · see citing works

Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists

Ashton, J. C., Wright, J., McPartland, J. M., & Tyndall, J. D. A. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784567716 · Cited by 91 · see citing works